TiGenix and Takeda Get EU Nod for Crohns Therapy
TiGenix and Takeda’s Alofisel has won clearance from the European Commission making it the first allogeneic stem cell therapy to be approved for use in Europe.Alofisel previously known as...
View ArticleTakedas Alofisel becomes Europes first allogeneic stem cell therapy
Will treat perianal fistulas in adult patients with Crohn’s disease
View ArticleAlofisel darvadstrocel Receives Approval to Treat Complex Perianal Fistulas...
NewsAlofisel offers a new treatment option for patientswho do not respond to current available therapies and may be subject to numerous invasive surgeries.
View ArticleEsperite ESP The Cell Factory presents preclinical results on the new...
Esperite with its biotech company The Cell Factory has acquired from OPBG the full rights to the IP and the international patent family covering the invention and the therapeutic use of the...
View ArticleRedHill Biopharma RDHL Commercial stage GIfocused R&D pharma
Edison Investment Research Pharmaceutical & healthcare RedHill Biopharma 2017 saw RedHill transformed from a pure drug developer into a commercialstage revenuegenerating specialty pharma company...
View ArticleFirst allogenic stem cell therapy approved by EC
The first allogenic stem cell therapy Alofisel darvadstrocel from TiGenix and Takeda Pharmaceutical Company has received marketing authorisation approval from the EC for the treatment of complex...
View ArticleNew review explores potentially safer therapies for treating chronic...
An estimated 2 million people in the U.S. are addicted to prescription opioids powerful doctorprescribed medications for chronic or severe pain. The drugs are commonly prescribed to treat...
View ArticleCrohn's Disease CD Market Insight Epidemiology and Market Forecast 2027...
DelveInsight's "Crohn's Disease CD Market Insight Epidemiology and Market Forecast 2027" report provides a detailed analysis of the Crohn's Disease CD epidemiology and market outlook for the...
View ArticleBetter Outcomes After EndtoEnd Ileocecal Anastomosis in Crohn's
Following intestinal resection in Crohn's disease endtoend ileocecal anastomosis ETEA is associated with better outcomes than is sidetoside anastomosis STSA according to a registry study. Reuters...
View ArticleNeovacs SA ALNEV Pharmaceuticals Healthcare Deals and Alliances Profile...
SummaryNeovacs SA Neovacs is a biotechnology company which develops various therapeutic vaccines for autoimmune disorders inflammatory diseases and cancers. The company offers TNF kinoid and IFNa...
View ArticleEC approves Alofisel for complex perianal fistulae in Crohns disease
The EC has approved Alofisel for the treatment of complex perianal fistulae in adult patients with nonactivemildly active luminal Crohns disease...The post
View ArticleTakeda to invest 25m and create up to 70 new roles
TiGenix and Takeda Pharmaceutical Company Limited last week announced that the European Commission has approved Alofisel previously Cx601 for the treatment of complex perianal fistulae in adult...
View ArticleCalciMedica Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report...
SummaryCalciMedica Inc CalciMedica is a pharmaceutical company that develops small molecule drugs for the treatment of inflammatory and autoimmune disorders and organ transplant rejection. The...
View ArticleGalapagos NV GLPG Financial and Strategic SWOT Analysis Review Report Updated...
SummaryGalapagos NV Galapagos is a biotechnology company that discovers and develops pharmaceutical products. The company's product pipeline encompasses investigational candidates targeted at the...
View ArticleCelgene's COO quits after troubles with new drugs
Celgenes chief operating officer and inflammatory diseases guru Scott Smith has quit the company in the aftermath of the FDAs rejection of a key multiple sclerosis pill and a latestage trial failure in...
View ArticleAnalysis challenges link between pain medications and inflammatory bowel disease
Wiley Contrary to generally accepted belief a recent review and analysis of published studies did not reveal a consistent association between the use of nonsteroidal antiinflammatory drugs NSAIDs or...
View ArticleMorphoSys Announces Approvals for TremfyaR Guselkumab for the Treatment of...
DGAPNews MorphoSys AG Key words Regulatory Approval05.04.2018 1607 The issuer is solely responsible for the content of this announcement.PlaneggMunich Germany April 5 2018MorphoSys Announces Approvals...
View ArticleExclusive Enteral Nutrition for Pediatric Crohn's Varies Significantly Worldwide
Reuters Health Information
View ArticleAbbVie Samsung BioepisBiogen settle patent litigation
Samsung Bioepis Co. Ltd. and partner Biogen Inc. have settled patent litigation with AbbVie Inc. surrounding Imraldi SB5 a biosimilar of AbbVie's Humira adalimumab. Under the settlement SamsungBiogen...
View ArticleMorphoSys Announces Approval of TremfyaR Guselkumab for the Treatment of...
DGAPNews MorphoSys AG Key words Regulatory Approval06.04.2018 0730 The issuer is solely responsible for the content of this announcement.PlaneggMunich Germany April 6 2018MorphoSys Announces Approval...
View Article